The Times reports that AstraZeneca, the U.K.'s most valuable public company, is looking to move its listing from London to the U.S.
BreakdownGenerated by LeadStory AI
- AstraZeneca is reportedly considering moving its listing from London to the US.
- CEO Pascal Soriot is said to be driving the potential move. 11s
- AstraZeneca is the UK's most valuable public company, making up a significant portion of the FTSE 100. 17s
- Key factors include valuation differences, tax regimes, and regulatory challenges in the UK. 1m 16s
- The company is reportedly frustrated with UK restrictions on new medicine approvals. 1m 57s